Open Actively Recruiting

Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke


Brief Summary

This study explores the effects of telerehabilitation and a study medication on rehabilitation outcomes in patients with stroke resulting in arm weakness. Patients with arm weakness due to a stroke that happened in the past 30 days will be randomized into one of three groups: [1] TR and placebo (a sugar pill) on top of usual care; [2] TR and a medication (Sinemet 25/100) on top of usual care; [3] or usual care alone (no TR and no pill, but people in this group will be offered TR once the study is done). TR consists of 70 minutes/day of activities targeting arm function, 6 days a week for 6 weeks.

Primary Purpose
Study Type
Phase I/II


Healthy Volunteers
Minimum Age
18 Years
Maximum Age


  • Age 18 years or older
  • Stroke that has been radiologically verified and has time of onset 30 days or less from the time of randomization
  • ARAT score of <32 (out of 57) at Visit 1
  • At Visit 1, either
    • BBT score with affected arm is at least 1 block in 60 seconds OR
    • There is a visible flicker in each of the following movements with gravity eliminated: wrist extension and finger flexion
  • At Visit 1, either
    • The range of motion against gravity must be ≥45 degrees in both the paretic shoulder and elbow OR
    • the patient must be able to use at least 3 different telerehab system input devices
  • Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent)


  • A major, active, coexistent neurological or psychiatric disease (e.g., alcoholism or dementia)
  • Major medical disorder that reduces subject's ability to comply with study procedures
  • Severe depression, defined as CES-D score >24 at screening visit
  • Significant cognitive impairment, defined as presence of either
    • Montreal Cognitive Assessment (MoCA) score <22 OR
    • Trail Making Test: Part A score ≤14
    • Note that lower scores may be permitted if due to aphasia and if the patient is specifically allowed by Dr. Cramer
  • Deficits in communication that interfere with reasonable study participation
  • Lacking visual acuity, with or without corrective lens, of 20/50 or better in at least one eye
  • Life expectancy <6 months
  • Pregnant
  • Botox to arms, legs or trunk in the preceding 4 months, or expectation that Botox will be administered to the arm, leg or trunk within 3 months of study enrollment
  • Unable to successfully perform all 3 rehabilitation exercise test examples
  • Unable or unwilling to perform study procedures/therapy or attend study visits, or expectation of noncompliance with study procedures/therapy
  • Non-English or non-Spanish speaking, such that subject does not speak either language sufficiently to comply with study procedures
  • Isolation due to active COVID-19
  • Any contraindication to L-Dopa:
    • Patient is currently taking a monoamine oxidase inhibitor; if the patient took such a drug in the past, it must be discontinued at least two weeks prior to study enrollment
    • Known hypersensitivity to any component of Sinemet
    • Narrow-angle glaucoma; if wide-angle glaucoma is present, the patient can only be enrolled with explicit written approval from their ophthalmologist
    • History of melanoma or suspected melanoma
    • Patient is currently taking phenytoin, papaverine, isoniazid, or a dopamine D2 receptor antagonist (such as a phenothiazine, butyrophenone, or risperidone)
    • Currently taking a direct dopaminergic agonist
  • Expectation that subject will not have single domicile address during 6 weeks of therapy that has either Verizon wireless reception or a home WiFi network and that has space for TR system, and is within 30 miles of Cal Rehab

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Brain/Neurological Diseases
  • UCLA Westwood
For Providers
For detailed technical eligibility, visit